Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

Response to humanized defucosylated anti-CCR4 antibody (KW-0761) in a representative patient with acute-type adult T-cell leukemia–lymphoma. The time course of lymphocytes and adult T-cell ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

anti-CD7 CAR-T cell therapy for pediatric and adult patients with relapsed or refractory (R/R) T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma (T-ALL/LBL). "The data we have ...

My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left without hope.” ...

My practice included obstetrics, pediatrics and adult care ... Pac-Men tracking down and destroying leukemia cells). Research to develop CAR T-cell therapy began in the 1950s with the development ...

Using human T cells and leukemia cells in specialized mouse models ... Children's Hospital Colorado – which see more than two million adult and pediatric patient visits yearly.

That's partly because younger people can tolerate more intensive treatments, such as stem cell therapies ... Florida's leukemia health care, the findings highlighted opportunities. "You don't ...